We are excited to announce that Biocytogen will exhibit at the 6th mRNA-Based Therapeutics Summit from July 20th - 22nd. Major acquisitions and investments in the mRNA field are driving growth, with assets in vivo CAR-T, gene editing, and cancer immunotherapies demonstrating increasing clinical promise and commercial potential. Come visit our booth to learn more about how our target-humanized mouse models are driving innovative drug discovery!
What is the 6th mRNA-Based Therapeutics Summit
The 6th mRNA-Based Therapeutics Summit is a premier meeting for mRNA professionals. 250+ industry leaders gather to discuss the latest breakthroughs and technologies, making this a fantastic platform for collaboration opportunities. This year’s program covers everything from new data to next-gen designs, spread across three tracks: Discovery, Pre-Clinical & Clinical Development, and Manufacturing & CMC.
Event Overview
Date: July 20th - 22nd, 2026
Venue: The Westin Boston Seaport District, 425 Summer St, Boston, MA 02210
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to connecting with you in Boston, MA!
